|
|
|
|
|
28.08.26 - 14:21
|
AstraZeneca Buy (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca mit einem Kursziel von 17500 Pence auf "Buy" belassen. Die zusätzliche Gabe von TTR-Stabilisatoren habe dem Herzmittel Wainua in der CARDIO-TTRansform-Studie die ......
|
|
|
|
|
|
|
|
|
|
|
|
|
27.08.26 - 15:24
|
Invesco Ltd: Form 8.3 - Advanced Medical Solutions Group Plc; Public dealing disclosure (Cision)
|
|
|
FORM 8.3
PUBLIC DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)
1. KEY
INFORMATION
(a) Full name of Invesco Ltd.
discloser:
(b) Owner or
controller of
interests and
short
positions
disclosed, if
different
from 1(a):
The naming of
nominee or
vehicle
companies is
insufficient.
For a trust,
the
trustee(s),
settlor and...
|
|
|
27.08.26 - 15:24
|
Carna Health Taps Multidisciplinary Healthcare and Technology Experts to Guide the Future of Cardio-Kidney-Metabolic Care (Business Wire)
|
|
|
Strategic leadership additions support Carna Health's continued global growth, building on key partnerships and positioning the company for U.S. market entryBOSTON--(BUSINESS WIRE)--Carna Health, an AI-enabled digital health company revolutionizing Cardio-Kidney-Metabolic (CKM) care, today announced several strategic leadership appointments, including the addition of multidisciplinary healthcare and technology experts as strategic advisors. The appointments bring expertise across AI, business development, technology, and public health to support the company's continued growth and global expansion, building on strategic partnerships with Siemens Healthineers and Renalytix as Carna Health advances toward U.S. market entry. The strategic advisors will also guide executive leadership as the company expands large-scale CKM prevention programs into new regions and works toward its goal of screening 100 million lives worldwide by 2030.
In addition to the advisors named below, Justin Nguyen has officially joine...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27.08.26 - 08:18
|
Tezspire CROSSING trial met primary endpoints (Cision)
|
|
|
27 August 2026
Tezspire demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52
Efficacy in a third epithelial-driven inflammatory disease supports broad potential of Tezspire
Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis (EoE) showed that AstraZeneca and Amgen's Tezspire (tezepelumab) demonstrated statistically...
|
|
|
27.08.26 - 04:12
|
China′s Akeso says cancer drug beat AstraZeneca′s Imfinzi in phase 3 trial (SCMP)
|
|
|
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca's Imfinzi in a head-to-head phase-three trial for biliary tract cancer.
The result represents another breakthrough for Akeso's ivonescimab – which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal – as China's biopharma industry increasingly looks to compete on the global stage.
The Chinese trial tested ivonescimab and chemotherapy against......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
